Menu
GeneBe

DSTYK

dual serine/threonine and tyrosine protein kinase

Basic information

Region (hg38): 1:205142504-205211702

Previous symbols: [ "RIPK5", "SPG23" ]

Links

ENSG00000133059NCBI:25778OMIM:612666HGNC:29043Uniprot:Q6XUX3AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • congenital anomalies of kidney and urinary tract 1 (Definitive), mode of inheritance: AD
  • congenital anomalies of kidney and urinary tract 1 (Limited), mode of inheritance: AR
  • renal agenesis, unilateral (Supportive), mode of inheritance: AD
  • hereditary spastic paraplegia 23 (Supportive), mode of inheritance: AR
  • congenital anomalies of kidney and urinary tract 1 (Limited), mode of inheritance: AD
  • complex hereditary spastic paraplegia (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Congenital anomalies of the kidney and urinary tract, 1ADRenalMonitoring and intervention related to vesicoureteral reflux may be beneficial in terms of helping to preserve renal functionCraniofacial; Dermatologic; Neurologic; Renal17273976; 28157540; 23862974

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the DSTYK gene.

  • not provided (129 variants)
  • Inborn genetic diseases (25 variants)
  • Congenital anomalies of kidney and urinary tract 1 (14 variants)
  • Hereditary spastic paraplegia 23 (7 variants)
  • not specified (4 variants)
  • DSTYK-related condition (2 variants)
  • Chronic kidney disease (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the DSTYK gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
22
clinvar
7
clinvar
30
missense
76
clinvar
6
clinvar
3
clinvar
85
nonsense
1
clinvar
1
start loss
0
frameshift
1
clinvar
2
clinvar
3
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
0
splice region
5
5
non coding
6
clinvar
18
clinvar
24
Total 0 2 80 34 28

Variants in DSTYK

This is a list of pathogenic ClinVar variants found in the DSTYK region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-205145663-GGATTACTGGTGCGTGCCAGCATGCCCGGCTAATTTGCAACTCATCTTATACACCTACCTGGGGACCTGTTTTACAAACTCTCGGGCTGAACACAGGGGCCAGACCACAGTTATTGGGGATTAGGCAGATGGAGGGAGACTACTCACTTCCACTGTCTACTTCCTCGTCTACCTGTTTTTCGGAATCTAATGGACCAGTTTGGTTGAGGAAGGCTTGAAGTCAAGTGCATCTGAGATGCACCAATATTTAAATTGTTCCCCTTCCTCTGCCTAGAATCAGAATTTCTTTCCTCAAGCACACTTCATGAGGAACCCTCCAAAAGACCACCCACCCGCCTCCCACCTTTCAGGGAAACTTCCCAGACACTAGCACACAGGGGTGAGGGGCACACACAGAACTACCAGAGGAGGGTTTTTCTCTTTCGTCTGCTGCTTTTTTTCTTCTAACAGATTTTTAAAAAGGTAAAAAGAAGGAACAAATTGCGGGAGAAATCGTGGTTAAAAGCTCATTGATCAAGTTTTCCAAACGTCAGTGTGTTAGATTCAAACACAAAAAGAAAAATTTCTGATTGTGTTAAGTTTTAAAAACAAGCTGGTTTTCTTCCAGTATGTTTGTACATAGGCCATGGCCTCCAATCATCTCCCACCTCTCAGTTCTCACCCAAATACTTCGCATTGGGTTGGTTTTGCTTAGACACTCACTCCTAAGTACCATGTTATCTGGAGCTTTCCCACTTTGAGATGAAAAGAGGTAAACAAAAGAAAAGACTCAAAGGTAAAAGAACAGATTCTGTTCTGGGGTTAGCAGTAACTCTAAATCCAATAACTCCTGTGTGTATGTCTATATAGATAGAGATATAGACACACACACATATATACATATACACACAAATATATGCATACACATTCTATTTTTTTTTTTTTTTTGAGACAGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAATGGCATGATCTCGGCTCACTGCAACCTCCGCCTCCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTATCTTGGATTACAGGCATGCACCACCACGCCCGGCTAATTTTTTGTATCTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGCTGCTCTTGAACTCTGGACCTTGTGATCCGCCCGCCTCAGCCTCCCAAAGTGCTGAGATTACAGGCGTGAGCCACCATGCCTGGCCTCTTTTTTTTTTTTTTTCCTCTTTTCAGGGCCTCTTGGTGATGTAACAGTGAAACCCTCCCCCAGAAACCAGGGATATGTGGTCCTATAAATGTAAACACACTGGCACTATGAGGAACAGATAGCTCTGTTTCTAGCTCCCTCACTGGGACTTCTGACCATTGCAACCTGAGATACCTGGCTGCAGACAGCAGGAACCAGACATCCACAAGTTATTGTTTTTGTCCCCATGTTTTCATAATCCCAGAACTAAGCTCAAATTTTCTGAGTCCTGACTAAACTATTCCTAGCTAGAGCCAAAAATCATGAGAATGAGATTTTTTAACACTATTGCCACTGCAGTGTCCCGCTTGCTGTCTTAGAAGTATATACAGTGAAAAGACAATGGTAACATCTGCCTCCTTTTCATTTGTGAAGCCAGAACACCACATTCCTCAGCTTTTACACATCTGAGACACTTTTTTGCTAAAGGGATAGCTTGGCGCTTCAGTGAGCTGCTGAATATGCTCAGTCATTCAACTCTTCACTGTCCAGGAGTCATCCCTGCCTGGGAAGGTTCCAAGTTTCCCAGCAAGCACCAGTTCCCTTGGGAGTGTGTCCTATAGTGAATAAATGTCAAATTCTCCCCATGGCCAAAAGGTGAGGGGGAAGGAAATAACTAGAGAGTGAAAGAGAAAGGTCTTTGCTTTCAAGTAGAATCATCTAGTCCTCTGTTTGGCTGCTCAGAATTGGACTTGCAGAGCCGATTCATGATGCCCTGGAGCATGGGCTGGACAATGCCCAAGAGAGGCCTCTTCAAGGGGTCGCCATCCCAACAGGCTTCCATCAACTGCCAGCACTCCTCATCAAACACAGGAAGACGTTCTGGGCGAGCCCCTAGAGAAAGGAGCATGGAAACAAGATCACAGTGAGAGGGACCCAGCACAACAAAGAGGCATGACCAGCTCAAAGGCTGACTTCCCAGTGGGGCTCAGAATACTAAGAATGCAAGGAGTTTTGACTTCGATTGCAAACATCTAGGTTAGAACCTAACAGTAAGAGCAATTAAAAAAAAAAAGAAAGAAAGAAAAAGAAAAGAAAAACTGGAACACATTAGCATATGAAGTTGAAGAATCGGACATTTTTTAAAAAAGACTTTTCGAGATAGTTCAATAGAGAGTTGACTTGAAGCAAAGGTTGACTTAAATATCTTTTCTGGATTCATGACAGTTTAAACGTATCTACGGCCCTGCTATGGAGTGGCCAGATGGGATGACAGGAGACCCGGTGACATTGCCTGGGCTCAGTCTGCGCTAGCCAGGGGAGTTAGGACAAGGTAGTACTTGTGGCTCTTACCCCTCCGCACATTGTTCCAGAGATGGTCTTTGCTAGCACACCTCTCAAATGCCTCAGGGAGCTTGACAGAGCCTGAGCAGATATACCAGAAAAGAATTCCAAAAGCGTAGACATCCACGGAATTATCGTACTTCCCTGATGGCAAGAAAGGATGAAACGTAATGAGCCACAGAGAGTCAGGCAGCAGCATCTACACCACCTTGCCTCAGTAGAGGGTTGGCTTTTTCCAAAGCTTTTAACAACTATTATCTCTCAATAACAACCCTGCCAGGTAGGCAGGGTACATTTATAATGCCCATTTTACAATACAATCAACTAAGACATTGGGAGGTCACAGCTCAATACTAAGAGAGCCAAGCCTAGAACTTGACAAAGGAGAAGGAAAATAAGGCCTTTCATTCTGCTAGGACAGTCAAAAAGATTAATCACAAAAGGTCATATTAGGGAAATAAAGTTGGAAATACAGGTGGGTAGGTATGTTGGAACCAGAATATAATAATTTTTAAAGTCAGGTAGAAGAGTCTGGATTCAGTGAGAAGCAGGAAGTCATTTATGTTTTAGAGTAGGAGGTGACATGAAGAATATAATATTTTAGAAAGATGATTCCAACAGCAATAGGGTGGACTGTAATAGAAACAATAAAAGAAATTTAAGTATGAAGTAGCCAAAATAGAATAACAGCAGTGGAATTAGAAAGTGTTTTTTTTTTTTTTTTGAGATGGAGTTTGACTCTTATTGCCCAGGCTGGAGTGCAGTGGCATGATCTCGGCTCACCACAACTTCTGCCTGCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCATGTGCCACCACGCCCGGCCTATTTTGTATTTTTAGTAGAGATGGGGTTTCTCCATGTTGGTCAGGGTAGTCTTGAACTCCTGACCTCAGGCGATCCACCTGCCTTGGCTTCCCAAAGTGCTGGGATTACGACATGAGCCACCGCACCTGGCCGAAAGTTTTTTTTTTTTTAAGTAAATCAAGAGAAAGAAAAATGATGACTATCTACTTGGTTCAGATGTTGAGTACGACTACAGCTGTCTCACTAACACCTAATCCTTACATGTATCACCCAGTGAAGGGCTGGGGGAAGACTCGTACATGAAATGAAAGAAATTTAAATATATTGCTAATTTTAACTCTTACCAATACTAATGACTGACCAGGGACTACCTTTCTATCTTCGCTGGCAATGGAACAATCATTCCCATCACTTGGGCTCAAAACCGTGGAGTCATCTTTTAGTCATTCTTTTCTGTTCACTAACCATATCAAGTTAGCACCAAAATTTTGTTCATTCTTCCTCTGAATTAATCTCAAATTTCTCACGTTTGTTTGTTTTAGCACTAACACCAGCTTAATCATGGAGGCAACCATAGAAGACCAGCTATCTAGTCTTACCTTGGTTCTTCCCAAATCATCTTTACCTACTGTTGCTAAAGCTCATCTTCTATCAACATTTTCCTCTGTCCCCTACTCAAAAGCTCAGTAGCTCCTTAAGTCT-CCTCAAGGAGCAGGACTACA Hereditary spastic paraplegia 23 Pathogenic (May 13, 2019)417786
1-205147507-A-T Benign (Nov 10, 2018)1244575
1-205147566-A-T Uncertain significance (Oct 18, 2023)1444806
1-205147572-C-A Chronic kidney disease Uncertain significance (Oct 05, 2023)915849
1-205147572-C-T Uncertain significance (Jul 28, 2023)2441040
1-205147581-T-C Uncertain significance (Oct 19, 2022)2188846
1-205147586-G-C Uncertain significance (Apr 01, 2024)3234471
1-205147593-C-G Uncertain significance (Jan 02, 2024)1400725
1-205147601-G-A DSTYK-related disorder Likely benign (Aug 01, 2022)2071647
1-205147623-T-C Uncertain significance (Jul 21, 2023)2900098
1-205147630-G-A Likely benign (Dec 21, 2023)2988479
1-205147632-G-A Uncertain significance (Nov 17, 2023)2711991
1-205147647-T-C Uncertain significance (Nov 04, 2023)2693158
1-205147648-G-A DSTYK-related disorder Uncertain significance (Feb 14, 2024)3061210
1-205147675-G-A Likely benign (May 16, 2023)2863337
1-205147730-C-T Uncertain significance (Jan 22, 2024)2989743
1-205147743-C-A Congenital anomalies of kidney and urinary tract 1 Uncertain significance (Feb 05, 2020)828135
1-205147744-C-G Likely benign (Apr 01, 2021)1596334
1-205147915-T-TA Benign (May 11, 2021)1220583
1-205148279-G-A Uncertain significance (Sep 16, 2018)633653
1-205148288-T-C Uncertain significance (Aug 01, 2023)2777863
1-205150434-GC-G Benign (Nov 10, 2018)1297990
1-205150453-C-T Benign (Nov 10, 2018)1240584
1-205150674-C-T Uncertain significance (Mar 02, 2023)2842271
1-205150737-T-C not specified Uncertain significance (Oct 17, 2023)3086042

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
DSTYKprotein_codingprotein_codingENST00000367162 1369096
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.5130.4871256600871257470.000346
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.594345370.8070.00003046046
Missense in Polyphen113173.40.651661878
Synonymous-0.1742122091.020.00001111847
Loss of Function4.901045.80.2180.00000266486

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001110.00110
Ashkenazi Jewish0.000.00
East Asian0.0001630.000163
Finnish0.000.00
European (Non-Finnish)0.0004320.000422
Middle Eastern0.0001630.000163
South Asian0.000.00
Other0.0005000.000489

dbNSFP

Source: dbNSFP

Function
FUNCTION: Acts as a positive regulator of ERK phosphorylation downstream of fibroblast growth factor-receptor activation (PubMed:23862974, PubMed:28157540). Involved in the regulation of both caspase-dependent apoptosis and caspase-independent cell death (PubMed:15178406). In the skin, it plays a predominant role in suppressing caspase-dependent apoptosis in response to UV stress in a range of dermal cell types (PubMed:28157540). {ECO:0000269|PubMed:15178406, ECO:0000269|PubMed:23862974, ECO:0000269|PubMed:28157540}.;
Disease
DISEASE: Spastic paraplegia 23 (SPG23) [MIM:270750]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG23 is an autosomal recessive form characterized by childhood-onset of gait difficulties and pigmentary abnormalities, including premature graying of the hair and vitiligo-like or hyperpigmented skin lesions. {ECO:0000269|PubMed:28157540}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.102

Intolerance Scores

loftool
0.340
rvis_EVS
0.09
rvis_percentile_EVS
60.68

Haploinsufficiency Scores

pHI
0.204
hipred
Y
hipred_score
0.515
ghis
0.556

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.774

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Dstyk
Phenotype
behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Zebrafish Information Network

Gene name
dstyk
Affected structure
cloaca
Phenotype tag
abnormal
Phenotype quality
malformed

Gene ontology

Biological process
peptidyl-tyrosine phosphorylation;positive regulation of kinase activity;negative regulation of apoptotic process;cellular response to fibroblast growth factor stimulus;positive regulation of fibroblast growth factor receptor signaling pathway;positive regulation of ERK1 and ERK2 cascade
Cellular component
cytoplasm;basolateral plasma membrane;apical plasma membrane;cell junction
Molecular function
protein serine/threonine kinase activity;protein serine/threonine/tyrosine kinase activity;protein tyrosine kinase activity;ATP binding